Saklayen built Cellino Biotech around a bet that laser-based cell engineering paired with machine learning can crack the unsolved economics of manufacturing autologous cell therapies — one of regenerative medicine's most stubborn production problems — at a scale that makes personalized treatments clinically viable.
Nabiha Saklayen co-founded Cellino Biotech, a Massachusetts-based regenerative medicine company developing autologous cell therapy manufacturing platforms that combine laser-based cell engineering with machine learning to produce personalized therapies at scale.
Under her leadership, Cellino has raised significant venture capital and advanced the scientific and engineering work required to bring individualized regenerative medicines to clinical reality. She was named a 2025 EY Entrepreneur of the Year New England Award winner. The company is working on a genuinely novel approach to one of the most challenging problems in regenerative medicine: how to manufacture autologous cell therapies in ways that are both scalable and economically accessible. Cellino's combination of precision laser technology, automation, and machine learning reflects a broader thesis - that manufacturing innovation may be as important as therapeutic innovation in determining which cell and gene therapies become widely accessible. Personalized cell therapies face a problem the industry has not yet solved at scale: the economics of making one-off biological products that are engineered specifically for single patients. Saklayen is working on one of the more credible technical paths toward solving it.
An invitation, extended to Powered readers.
